These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 20615448)
1. Proteasome inhibitors: Dozens of molecules and still counting. de Bettignies G; Coux O Biochimie; 2010 Nov; 92(11):1530-45. PubMed ID: 20615448 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of the ubiquitin-proteasome system by natural products for cancer therapy. Tsukamoto S; Yokosawa H Planta Med; 2010 Aug; 76(11):1064-74. PubMed ID: 20186654 [TBL] [Abstract][Full Text] [Related]
3. Small-molecule inhibitors of proteasome activity. Gaczynska M; Osmulski PA Methods Mol Biol; 2005; 301():3-22. PubMed ID: 15917622 [TBL] [Abstract][Full Text] [Related]
4. Retro hydrazino-azapeptoids as peptidomimetics of proteasome inhibitors. Aubin S; Martin B; Delcros JG; Arlot-Bonnemains Y; Baudy-Floc'h M J Med Chem; 2005 Jan; 48(1):330-4. PubMed ID: 15634028 [TBL] [Abstract][Full Text] [Related]
5. Noncovalent inhibition of 20S proteasome by pegylated dimerized inhibitors. Maréchal X; Pujol A; Richy N; Genin E; Basse N; Reboud-Ravaux M; Vidal J Eur J Med Chem; 2012 Jun; 52():322-7. PubMed ID: 22440858 [TBL] [Abstract][Full Text] [Related]
6. The role of proteasome in malignant diseases. Moran E; Nencioni A J BUON; 2007 Sep; 12 Suppl 1():S95-9. PubMed ID: 17935285 [TBL] [Abstract][Full Text] [Related]
7. Targeting the ubiquitin-proteasome pathway with inorganic compounds to fight cancer: a challenge for the future. Dalla Via L; Nardon C; Fregona D Future Med Chem; 2012 Mar; 4(4):525-43. PubMed ID: 22416778 [TBL] [Abstract][Full Text] [Related]
8. Drug discovery and assay development in the ubiquitin-proteasome system. Berkers CR; Ovaa H Biochem Soc Trans; 2010 Feb; 38(Pt 1):14-20. PubMed ID: 20074028 [TBL] [Abstract][Full Text] [Related]
9. The persisting challenge of selective and specific proteasome inhibition. Groll M; Huber R; Moroder L J Pept Sci; 2009 Feb; 15(2):58-66. PubMed ID: 19109822 [TBL] [Abstract][Full Text] [Related]
10. Proteasome inhibition up-regulates p53 and apoptosis-inducing factor in chondrocytes causing severe growth retardation in mice. Zaman F; Menendez-Benito V; Eriksson E; Chagin AS; Takigawa M; Fadeel B; Dantuma NP; Chrysis D; Sävendahl L Cancer Res; 2007 Oct; 67(20):10078-86. PubMed ID: 17942942 [TBL] [Abstract][Full Text] [Related]
14. [Proteasome and proteolysis]. Papapostolou D; Reboud-Ravaux M J Soc Biol; 2004; 198(3):263-78. PubMed ID: 15662944 [TBL] [Abstract][Full Text] [Related]
15. Proteasome inhibition: a new approach for the treatment of malignancies. Spano JP; Bay JO; Blay JY; Rixe O Bull Cancer; 2005 Nov; 92(11):E61-6, 945-52. PubMed ID: 16316823 [TBL] [Abstract][Full Text] [Related]
18. The development and pharmacology of proteasome inhibitors for the management and treatment of cancer. Ruggeri B; Miknyoczki S; Dorsey B; Hui AM Adv Pharmacol; 2009; 57():91-135. PubMed ID: 20230760 [TBL] [Abstract][Full Text] [Related]
19. Towards the control of intracellular protein turnover: mitochondrial Lon protease inhibitors versus proteasome inhibitors. Bayot A; Basse N; Lee I; Gareil M; Pirotte B; Bulteau AL; Friguet B; Reboud-Ravaux M Biochimie; 2008 Feb; 90(2):260-9. PubMed ID: 18021745 [TBL] [Abstract][Full Text] [Related]
20. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Meister S; Schubert U; Neubert K; Herrmann K; Burger R; Gramatzki M; Hahn S; Schreiber S; Wilhelm S; Herrmann M; Jäck HM; Voll RE Cancer Res; 2007 Feb; 67(4):1783-92. PubMed ID: 17308121 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]